Abstract
α2-Adrenoceptor antagonists, which can enhance synaptic norepinephrine levels by blocking feedback inhibition processes, are potentially useful in the treatment of disease states such as depression, memory impairment, impotence and sexual dysfunction. (10bS)-1,2,3,5,6,10b-Hexahydropyrrolo[2,1-a]isoquinoline oxalate (YSL-3S) was evaluated in severalin vitro biological tests to establish its pharmacological profile of activities as an α2-adrenoceptor antagonist. Saturation binding assay revealed that [3H]rauwolscine bound to the α2-adrenoceptors with a Kd value of 6.3±0.5nM and a Bmax value of 251±39 fmol/mg protein in rat cortical synaptic membranes. Competitive binding assay showed that YSL-3S inhibited the binding of [3H]rauwolscine (1nM) in a concentration-dependent manner with a Ki value of 98.2±12.1nM while it did not inhibit the binding of [3H]cytisine (1.25nM) to neuronal nicotinic cholinergic receptors. The Ki values of yohimbine, clonidine and norepinephrine for [3H]rauwolscine binding were 15.8±1.0, 40.1±5.9 and 40.0±11.5nM, respectively. In addition, the binding affinity of YSL-3S for a2-adrenoceptors was higher, than that of its antipode and the racemic mixture. The functional activity of YSL-3S at the presynaptic α2-adrenoceptors was assessed using the prostatic portion of the rat vas deferens. Clonidine inhibited field-stimulated contractions of the vas deference in a dose-dependent manner. The presence of YSL-3S or yohimbine caused a parallel, rightward the dose-response curve of clonidine in a dose-dependent manner, indicating an antagonistic action at the presynaptic α2-adrenoceptors. The pA2 values of yohimbine and YSL-3S were 7.66±0.13 and 6.64±0.18, respectively. The results indicate that YSL-3S acts as a competitive antagonist at presynaptic α2-adrenoceptors with a potency approximately ten times lower than yohimbine, but is devoid of binding affinity for neuronal nicotinic cholinergic receptors.
This is a preview of subscription content, log in via an institution to check access.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Cheng, Y. C., and Prusoff, W. H., Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction,Biochem. Pharmacol., 22, 3099–3108 (1973).
Doxey, J. C., Smith, C. F. C., and Walker, J. M., Selectivity of blocking agents for pre- and postsynaptic a-adrenoceptors.Br. J. Pharmacol., 60, 91–96 (1977).
Giardina, W. J., Buckner, S. A., Hancock, A. A., Lee, J.-Y., Wismer, C. T., and DeBernadis, J. F., A-75169 HCl: Pharmacological profile and ocular pharmacology studies of a new α2 antagonist,Drug Development Res., 28, 56–64 (1993).
Glowinski, J., and Iverson, L. L., Regional studies of catecholamines in the rat brain: I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]DOPA in various regions of the brain,J. Neurochem., 13, 655–669 (1966).
Goldberg, M. R., and Robertson, D., Yohimbine: A pharmacological probe of the α2-adrenoceptor. Pharmacol. Rev., 35, 143–180 (1983).
Hancock, A. A., Buckner, S. A., Giardina, W.J, Brune, M. E., Lee, J. Y., Morse, P. A., Oheim, K. W., Stanisic, D. S., Warner, R. B., Kerkman, D. J. and DeBernardis, J. F., Preclinical pharmacological actions of (±)-(1′R*, 3R*)-3-phenyl-1-[(1′,2′,3′,4′-tetrahydro-5′,6′-methylene-dioxy-1′-naphthalenyl)methyl] pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine,J. Pharmacol. Exp. Ther., 272, 1160–1169 (1995).
Hedler, M., Stamm, G., Weitzell, R., and Starke, K., Functional characterization of central a-adrenoceptors by yohimbine diastereoisomers,Eur. J. Pharmacol., 70, 43–49 (1981).
Lee, Y. S., Kang, D. W., Lee, S. J., and Park, H., Asymmetric synthesis of both enantiomers of pyrrolidinoisoquinoline derivatives from L -malic acid and L -tartaric acid.J. Org. Chem., 60, 7149–7152 (1995).
Lee, Y. S., Kim, S. H., Jung, S. H., Lee, S. J., and Park, H., Studies on the site-selective N-acyliminium ion cyclization: synthesis of (±)-glochidine and (±)-glochidicine.Heterocycles, 37, 303–309 (1994).
Lefkowitz, R. J., Hoffman, B. B. and Taylor, P., Neurotransmission: The autonomic and somatic motor nervous systems, In Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W., and Gilman, A. G. (Eds.).Goodman and Gilman’s The Pharmacological Basis of Therapeutics. McGraw-Hill, Singapore, pp. 105–139, 1996.
Leitch, I. M., Rawlow, A., King, R. G., Boura, A. L., Bremner, J. B., and Browne, E. J., The action of 1,2,3,5,6,11b-hexahydro-[1]-benzothieno[3,2-g]indolizine hydrochloride (ADT-16) on peripheral and central responses mediated by 5-hydroxytryptaminergic and adrenergic systems of the rat,J. Pharm. Pharmacol., 46 (10), 820–825 (1994).
Lowry, O. N. and Rosebrough, N. J., Protein measurement with Folin phenol reagent,J. Biol. Chem., 193, 265–275 (1951).
Pabreza, L. A., Dhawan, S. and Kellar, K. J., [3H]Cytisine binding to nicotinic cholinergic receptors in brain,Molecular Pharmacology, 39, 9–12 (1991).
Perry, B. D. and U’Prichard, D. C., [3H]Rauwolscine (α-yohimbine): A specific antagonist radioligand for brain α2-adrenergic receptors.Eur. J. Pharmacol., 76, 461–464 (1981).
Pinder, R. M. and Wieringa, J. H., Third-generation antidepressants.Medicinal Research Reviews, 13, 259–325 (1993).
Prous, J. R., Antidepressants, In Prous, J. R. (Ed.).The Year’s Drug News. Prous Science, Barcelona, pp. 53–60 (1995).
Richelson, E., Pharmacology of antidepressant.Psychopathol., 20 (suppl 1), 1–12 (1987).
Schild, H. O., pA2 A new scale for the measurement of drug antagonism,Br. J. Pharmacol., 2, 189–206 (1947).
Tallarida, R. J., Cowman, A. and Adler, M. W., pA2 and receptor differentiation: A statistical analysis of competitive antagonism,Life Sci., 25, 637–654 (1979).
Weich, N. L. and Ursillo, R. C., Acceleration of despiramine-induced decrease of rat corticocerebral β-adrenergic receptors by yohimbine,Commun. Psychopharmacol. 4, 95–100 (1980).
Zukin, S. R., Young, A. B. and Snyder, S. H., Gammaaminobutyric acid binding to receptor sites in the rat central nervous system,Proc. Natl. Acad. Sci. USA, 71, 4802–4807 (1974).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chung, SH., Yook, J., Min, B.J. et al. Pharmacological characterization of (10bS)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline oxalate (YSL-3S) as a new α2-adrenoceptor antagonist. Arch Pharm Res 23, 353–359 (2000). https://doi.org/10.1007/BF02975447
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02975447